Category: Press Releases

Intensity Therapeutics Issued New Patents for Technology Platform

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338. “Intensity’s DfuseRxSM platform has identified our lead drug, INT230-6. This… Read more »

Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the US Food and… Read more »

Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that tumor regression and immune activation data generated by the Company’s lead drug, INT230-6, will be presented in a poster session at the American Academy of Cancer Research (AACR) meeting on April 5, 2017. The research being presented indicates that… Read more »

Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors… Read more »

Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997. “Intensity’s DfuseRxSM platform technology has identified our lead drug, INT230-6. This novel product has shown great promise in regressing tumors and extending life in murine models… Read more »

Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that Chief Medical Officer Dr. Ian B Walters will be presenting mechanism of action and other data in a poster session at the American Academy of Cancer Research (AACR) meeting on April 19, 2016. The research being presented indicates that… Read more »

Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that preclinical research from the Company and its collaborators at the National Cancer Institute (NCI) were selected for oral presentation at two important upcoming congresses. The results demonstrate the ability of Intensity’s proprietary product, INT230-6, to create a robust anti-cancer immunological… Read more »

Intensity Therapeutics Preclinical Results Show AntiCancer Synergy of INT230-6 with Anti-PD-1 Compounds

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune-based cancer therapy products, presented preclinical results from a study of the Company’s lead product, INT230-6, in combination with checkpoint inhibitors. The results show significantly increased antitumor response using a combination of INT230- 6 with an anti-PD-1 antibody compared to combined administration of anti-PD-1 and anti-CTLA-4… Read more »

Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that Douglas Hanahan, Riccardo Lencioni and Mario Sznol would join the Company’s newly formed Scientific Advisory Board (SAB). These worldrenowned scientists and physicians will provide research and development guidance on Intensity’s proprietary products and technology. The SAB members span… Read more »

Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum

Intensity Therapeutics, Inc. (private), developing novel immune based drug products to treat cancer, announced that President and CEO Lewis H. Bender has been invited to give a talk at the 10th Annual Value-Based Oncology Management Forum on Wednesday, October 14, 2015 at 4:00 PM in the Warwick Allerton Hotel in Chicago Illinois. Mr. Bender’s presentation… Read more »